Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Market watchers are expecting strong growth driven by the robust sales of Lilly's blockbuster medications, particularly the diabetes franchise. However, there are also concerns about potential headwinds from gene